JP2008531665A5 - - Google Patents

Download PDF

Info

Publication number
JP2008531665A5
JP2008531665A5 JP2007557572A JP2007557572A JP2008531665A5 JP 2008531665 A5 JP2008531665 A5 JP 2008531665A5 JP 2007557572 A JP2007557572 A JP 2007557572A JP 2007557572 A JP2007557572 A JP 2007557572A JP 2008531665 A5 JP2008531665 A5 JP 2008531665A5
Authority
JP
Japan
Prior art keywords
effective amount
pharmaceutically acceptable
pharmaceutically effective
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007557572A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008531665A (ja
Filing date
Publication date
Priority claimed from GBGB0504103.3A external-priority patent/GB0504103D0/en
Application filed filed Critical
Publication of JP2008531665A publication Critical patent/JP2008531665A/ja
Publication of JP2008531665A5 publication Critical patent/JP2008531665A5/ja
Pending legal-status Critical Current

Links

JP2007557572A 2005-02-28 2006-02-27 パーキンソン病の治療における2−(2−ニトロ−4−トリフルオロメチルベンゾイル)−1,3−シクロヘキサンジオンの使用 Pending JP2008531665A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0504103.3A GB0504103D0 (en) 2005-02-28 2005-02-28 Novel method
PCT/GB2006/000684 WO2006090177A1 (en) 2005-02-28 2006-02-27 USE OF 2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-l,3- CYCLOHEXANEDIONE IN THE TREATMENT OF PARKINSON'S DISEASE

Publications (2)

Publication Number Publication Date
JP2008531665A JP2008531665A (ja) 2008-08-14
JP2008531665A5 true JP2008531665A5 (enExample) 2009-03-12

Family

ID=34430351

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007557572A Pending JP2008531665A (ja) 2005-02-28 2006-02-27 パーキンソン病の治療における2−(2−ニトロ−4−トリフルオロメチルベンゾイル)−1,3−シクロヘキサンジオンの使用

Country Status (17)

Country Link
US (1) US20090326072A1 (enExample)
EP (1) EP1853241B1 (enExample)
JP (1) JP2008531665A (enExample)
CN (1) CN101163466B (enExample)
AT (1) ATE524171T1 (enExample)
AU (1) AU2006217650B2 (enExample)
BR (1) BRPI0609177A2 (enExample)
CA (1) CA2598517A1 (enExample)
DK (1) DK1853241T3 (enExample)
ES (1) ES2374761T3 (enExample)
GB (1) GB0504103D0 (enExample)
IL (1) IL185410A0 (enExample)
MX (1) MX2007010480A (enExample)
PT (1) PT1853241E (enExample)
RU (1) RU2420272C2 (enExample)
WO (1) WO2006090177A1 (enExample)
ZA (1) ZA200707486B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3311813B1 (en) 2007-08-27 2019-08-07 Dart Neuroscience (Cayman) Ltd Therapeutic isoxazole compounds
JP2011507910A (ja) * 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
US20100160295A1 (en) * 2008-11-06 2010-06-24 Synosia Therapeutics Treatment of restless leg syndrome and sleep disorders
PL2723320T3 (pl) * 2011-06-23 2016-06-30 Swedish Orphan Biovitrum Int Ab Ciekła kompozycja farmaceutyczna zawierająca nityzynon
CN103622942A (zh) * 2013-11-04 2014-03-12 江苏大学 左旋多巴/卡比多巴复方缓释混悬剂及其制备方法
MA42519A (fr) * 2015-07-29 2018-06-06 Takeda Gmbh Inhibiteur de la pde4 pour le traitement de la néphropathie diabétique
ITUB20160650A1 (it) 2016-02-11 2017-08-11 Dipharma S A Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione
US9783485B1 (en) 2016-11-30 2017-10-10 Dipharma S.A. Crystalline inhibitor of 4-hydroxyphenylpyruvate dioxygenase, and a process of synthesis and crystallization thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4780127A (en) * 1982-03-25 1988-10-25 Stauffer Chemical Company Certain 2-(substituted benzoyl)-1,3-cyclohexanediones and their use as herbicides
US5092919A (en) * 1991-01-15 1992-03-03 Imperial Chemical Industries Plc Certain 2-(2'-methyl-3',4'-trisubstituted benzoyl)-1,3-cyclohexanediones
DK0591275T3 (da) * 1991-06-24 1999-10-11 Zeneca Ltd Anvendelse af 2-(2-nitro-4-trifluormethylbenzoyl)-1,3-cyklohexandion til behandling af tyrosinæmi samt farmaceutiske sammen
FR2777781B1 (fr) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
US20050288187A1 (en) * 2002-07-03 2005-12-29 Hanauske-Abel Hartmut M Inhibitor development for 4-hydroxyphenylpyruvate dioxygenase, employing tyrosinemia 1 as a model for human diseases mediated by 2-oxoacid utilizing dioxygenases
EP1646377A4 (en) * 2003-07-11 2009-09-09 Merck & Co Inc TREATMENT OF MOVEMENT DISORDERS WITH METABOTROPIC GLUTAMATE 4 RECEPTOR POSITIVE ALLOSTERIC MODULATOR
AU2006347397A1 (en) * 2006-08-18 2008-02-21 Syngenta Limited Use of HPPD inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs
US20100160295A1 (en) * 2008-11-06 2010-06-24 Synosia Therapeutics Treatment of restless leg syndrome and sleep disorders

Similar Documents

Publication Publication Date Title
IL259851A (en) Compounds and methods of inhibiting antidepressant nhe mediator in the treatment of disorders associated with fluid retention or overload of salts and gastrointestinal disorders
WO2007131005A3 (en) Use of organic compounds
JP2009541489A5 (enExample)
CY1121781T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης της ρασαγιλινης και χρησεις αυτων
JP2012520883A5 (enExample)
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
JP2004307506A5 (enExample)
JP2006526031A5 (enExample)
CN109982699A (zh) 一种mor激动剂与kor激动剂的药物组合物及其用途
JP2013541514A5 (enExample)
JP2009545527A5 (enExample)
JP2008302206A5 (enExample)
JP2011522035A5 (enExample)
JP2011527299A5 (enExample)
JP2009537554A5 (enExample)
WO2008053446A3 (en) Benzoxazepine compounds, their preparation and use
JP2008531665A5 (enExample)
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
JP2004532828A5 (enExample)
IL185410A0 (en) Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of parkinson's disease
CN115916350A (zh) Akt抑制剂的单位剂量组合物
JP2008513426A5 (enExample)
JP2012532197A5 (enExample)
JP2007519646A5 (enExample)
WO2008120617A1 (ja) クローン病に伴う腸管狭窄の進展抑制用医薬組成物